{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058615","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.030614+00:00","generated_at":"2026-06-02T02:19:44.588442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fractyl Health Q1 net loss $3.3M; cash $121.4M; Remain-1 pivotal study H2 2024","bullets":["Net loss $3.3M vs $11.9M YoY; includes $17.1M non-cash gain from fair value changes.","Cash and cash equivalents $121.4M as of March 31, 2024; expected to fund operations through 2025.","Expects to initiate Remain-1 pivotal study for weight maintenance after GLP-1 discontinuation in H2 2024.","Topline data from Revitalize-1 pivotal T2D study anticipated in Q4 2024; enrollment completion expected Q2 2024.","Appointed Adrian Kimber as Chief Commercial Officer; Germany registry study shows HbA1c reduction >1% and weight loss >15 lbs at 3 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058615","json":"https://secwatch.observer/filing/0000950170-24-058615.json","markdown":"https://secwatch.observer/filing/0000950170-24-058615.md","text":"https://secwatch.observer/filing/0000950170-24-058615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/0000950170-24-058615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/guts-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:19:44.588442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73cd35e8edd4a329c2029316910d0c685cd21686","claim":"FRACTYL HEALTH, INC. reported first quarter 2024 results: revenue Revenue in the quarter ended March 31, 2024.","evidence_excerpt":"Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today reported its first quarter 2024 financial results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/0000950170-24-058615-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"Revenue in the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}